Bone Solutions (BSI) closed a private placement memorandum of US $1.5MM, surpassing its goal by achieving a funding round totaling >$1.7MM. BSI also has an additional $1.65MM in committed funding from Next Health, its distribution partner.
This funding precedes slated launch of BSI’s OsteoCrete™ magnesium-based bone void filler. The product is FDA-cleared for long bone and general orthopaedic applications.
Bone Solutions (BSI) closed a private placement memorandum of US $1.5MM, surpassing its goal by achieving a funding round totaling >$1.7MM. BSI also has an additional $1.65MM in committed funding from Next Health, its distribution partner.
This funding precedes slated launch of BSI's OsteoCrete™ magnesium-based...
Bone Solutions (BSI) closed a private placement memorandum of US $1.5MM, surpassing its goal by achieving a funding round totaling >$1.7MM. BSI also has an additional $1.65MM in committed funding from Next Health, its distribution partner.
This funding precedes slated launch of BSI’s OsteoCrete™ magnesium-based bone void filler. The product is FDA-cleared for long bone and general orthopaedic applications.
Copy to clipboard 
